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Introduction
Homozygous deficiency of each of the classical pathway
complement components (C1q, C1r, C1s, C4, C2) is
associated with an increased susceptibility to systemic
lupus erythematosus (SLE). The severity and the strength
of this association vary according to the position of the
missing component within the classical pathway of activa-
tion (C1>C4>C2) [1,2]. Inherited deficiencies of C1q
and C4 are invariably associated with the development of
a severe, lupus-like disease early in life, while C2 deficiency
is only weakly associated with a milder form of SLE, an
association which has most likely been overestimated [2].
In contrast, whereas deficiency of C3 predisposes to
recurrent pyogenic infections and membranoproliferative
glomerulonephritis, it is rarely associated with SLE [2].
This is a quite surprising finding, as C3 is the point of con-
vergence for all three complement-activating pathways
and therefore has the most substantial effect on all the
activities mediated by complement activation. The associ-
ation between complement deficiency and SLE appears
even more paradoxical: complement deficiency causes
SLE, and yet SLE causes activation and consumption of
complement. These clinical observations suggest that the
early part of the classical pathway plays a key protective
role against the development of SLE. A recently described
link between the complement system and apoptosis may
explain these apparently paradoxical findings.
Apoptosis and SLE
Apoptosis is an active process that leads to the pro-
grammed destruction of cells without the release of intra-
cellular contents into the extracellular microenvironment,
where they could cause an inflammatory reaction and
tissue damage. Apoptotic cells undergo a series of dis-
tinct physical changes, including alteration of the surface
lipid membrane, cytoskeletal disruption, cell shrinkage,
and a characteristic pattern of DNA fragmentation.
Although the apoptotic cell-death program is executed in
hours, the removal of dying cells is normally so rapid that
few cells are seen even in tissues such as the thymus,
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where up to 95% of cells undergo apoptosis. The mecha-
nisms whereby apoptotic cells are efficiently identified,
removed, and degraded by phagocytosis in mammalian
cells are not well understood. Several receptors/ligands
have been reported to play a role in the initial engulfment
of apoptotic cells in vitro. These include the avb3 vit-
ronectin receptor [3], the phosphatidylserine receptor
[4,5], CD36 [6], CD14 [7], scavenger receptor A [8],
receptors for low-density lipoprotein [9–11], and comple-
ment receptors 3 and 4 [12]. These different receptor/
ligand systems may function in conjunction with one
another, but individual types of phagocyte may show spe-
cific ligand/receptor preferences [4].
There is a mounting body of evidence that apoptotic cells
are the source of the autoantigens of lupus. First, Rosen
and his collaborators have demonstrated that apoptotic
cells express many of the nuclear autoantigens of SLE in
surface blebs and apoptotic bodies [13,14]. In addition,
negatively charged phospholipids, such as phosphatidylser-
ine, which are found predominantly in the inner lamella of
the cell membrane in healthy cells, are translocated to the
outer layer as part of the process of apoptosis, and the anti-
phospholipid autoantibodies, found in approximately one
third of patients with lupus, bind phosphatidylserine. Sec-
ondly, lupus autoantigens undergo post-translational modifi-
cation during the process of apoptosis and may be cleaved
or phosphorylated. This process could generate neo-epi-
topes of autoantigens, which might appear as ‘nonself’ to
the immune system [15]. Thirdly, recent experiments have
shown that injection of apoptotic cells into mouse strains
not normally susceptible to the development of SLE induces
an autoantibody response [16].
The finding that apoptotic cells may be the source of the
autoantigens in SLE raises two questions: 1) can a break-
down of the normal mechanisms of removal of apoptotic
cells promote the development of SLE? and 2) does the
complement system play a role in this clearance function?
Is SLE a disease of defective clearance of
apoptotic cells?
Recent studies have emphasised that apoptotic cells are
not immunologically inert, but rather have either positive or
negative effects, depending on the antigen-presenting cell
with which they interact. Is autoimmunity simply caused by
an increase in the load of autoantigens? For example, den-
dritic cells have been shown to be able to phagocytose
apoptotic cells via the avb5 receptor [17] and afterwards
efficiently present antigens derived from apoptotic cells to
MHC class I- and II-restricted T cells [17,18,19] in a dose-
dependent manner [20]. When macrophages are also
present, the presentation of apoptotic cells is markedly
inhibited. Two possible mechanisms might explain this
inhibition. One is that phagocytosis of apoptotic cells by
macrophages is so rapid and so efficient that the amount
of apoptotic material ingested by dendritic cells is min-
imised. The other is that phagocytosis of apoptotic cells
by macrophages induces the production of anti-inflamma-
tory cytokines (e.g. transforming growth factor-b) and
inhibits the production of pro-inflammatory cytokines (e.g.
interleukin-1b, tumour necrosis factor-a) [21,22]. This has
led to the hypothesis that an abnormality in any of these
pathways that are involved with the rapid clearance of
apoptotic material or with expression of its anti-inflamma-
tory activities may initiate autoimmunity. In the context of
this hypothesis, inherited defects in the mechanisms for
clearing apoptotic cells would be strong candidates as
susceptibility genes for SLE.
The role of complement in the clearance of
apoptotic cells
Complement was implicated for the first time in the clear-
ance of apoptotic cells by the observation that C1q could
bind in vitro specifically and directly to the surface blebs
of human keratinocytes that had been rendered apoptotic
by exposure to UVB [23]. This observation suggested that
C1q may promote the clearance of apoptotic cells, and
hence of exposed autoantigen, preventing stimulation of
the immune system. This hypothesis was tested in C1q-
deficient mice. These mice, on the hybrid genetic back-
ground (129 × C57BL/6), developed significant titres of
antinuclear antibodies and proliferative glomerulonephritis
characterised by an increased number of uncleared apop-
totic bodies [24], independently of C3 activation [25].
These findings, taken together, suggested that impairment
in the clearance of apoptotic cells might be the primary
defect. In addition, C4-deficient mice have recently been
shown to develop a lupus-like disease, while mice defi-
cient in complement receptors 1 and 2 (CR1 and CR2)
did not share this susceptibility [26], supporting the
hypothesis that complement deficiencies (C1q and C4) in
mice cause autoimmunity through mechanisms that do not
depend on CR1 and CR2.
However, studies by Mevorach and colleagues, using com-
plement-depleted sera and human monocyte-derived
macrophages  in vitro, suggested a role for both the classi-
cal and alternative pathways of complement in the phago-
cytosis of apoptotic cells [12]. To address the relative
contribution of different complement components to the
phagocytic removal of apoptotic cells in vivo, we studied
apoptotic cell clearance in complement-deficient mice. We
used an in vivo peritoneal model of apoptotic cell clear-
ance, in which the mice were initially injected intraperi-
toneally with thioglycollate, to induce recruitment of
inflammatory macrophages, and four days later the same
animals were injected with syngeneic apoptotic thymo-
cytes. The phagocytic uptake of the apoptotic thymocytes
by the elicited macrophages was significantly less in both
C1q- and C4-deficient mice than in wild-type control
animals. However, the phagocytic uptake was only partiallyimpaired in the C4-deficient mice compared with the C1q-
deficient animals. Furthermore, the C1q-deficient mice,
but not the C3- and C4-deficient animals, also exhibit a
defect in phagocytic uptake of apoptotic cells by resident
macrophages [27]. A similar phagocytic defect was also
observed in macrophages derived from the monocytes of
C1q-deficient humans and cultured in autologous serum
[26]. This defect was corrected in a dose-dependent
manner with purified human C1q. In this context, it is inter-
esting that monocyte-derived macrophages from humans
with SLE also exhibited impaired phagocytosis of apop-
totic cells in vitro [28]. These observations, taken
together, indicate that there is a hierarchy of importance
within the classical complement pathway in the phago-
cytic clearance of apoptotic cells that mirrors the hierarchy
of disease susceptibility in humans with complement defi-
ciency. Although there are at present no data that directly
address whether, and by what mechanism, impaired clear-
ance of apoptotic cells may initiate or exacerbate the
autoimmune state in vivo, one can hypothesise that the
delayed removal might cause two major effects. One
would be a change in the compartmentalisation of the
autoantigen, allowing leakage of autoantigens during sec-
ondary necrosis and access of soluble molecules to effi-
cient uptake by dendritic cells. Another effect would be
that the delay provides a source of apoptotic cells to (pro-
immune) populations of antigen-presenting cells from
which they are normally excluded.
Conclusion
All of these findings are compatible with the hypothesis
that complement deficiency causes SLE by impairment of
the physiological clearance of apoptotic cells by
macrophages. These uncleared apoptotic bodies in turn
may provide the source of the autoantigens that drive the
autoimmune response of SLE. A reduced ability of
macrophages to remove apoptotic cells at sites of inflam-
mation may promote the clearance of these cells by pro-
immune antigen-presenting cells, and if the necessary
pro-inflammatory cytokine milieu is present, this may drive
dendritic cell maturation and initiate an autoimmune
response followed by tissue damage and complement
activation. Autoimmunity in individuals deficient in the early
classical pathway components of complement may hence
be the consequence of impaired waste disposal. Further
experimentation is required to identify the receptors
involved and further delineate the mechanism of the hierar-
chy within the early classical pathway.
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